Semaglutide in One BBS10 Case

A case report describes one 31-year-old woman with BBS10-related Bardet-Biedl syndrome whose glycated hemoglobin, fasting glucose, body weight, insulin-resistance estimate and kidney markers improved during six months of semaglutide treatment^[1]. This is a case report, not a clinical trial. It has no control group, no randomization and no statistical test of a treatment effect. The observations document one clinical course, but they cannot establish that semaglutide caused every change or that people with Bardet-Biedl syndrome should expect a similar result.

What the report documented

The woman had obesity from childhood, bilateral postaxial polydactyly, progressive visual impairment, retinitis pigmentosa, hypogonadism, renal abnormalities and cognitive difficulties. Type 2 diabetes had been diagnosed nine years earlier during an infertility evaluation. The paper says she had been prescribed metformin but reported poor adherence and did not routinely monitor glucose. When admitted in April 2025, her body weight was 80 kg, body mass index was 31.6 kg/m2, fasting plasma glucose was 13.75 mmol/l and HbA1c was 8.5%^[2].

Whole-exome sequencing found two BBS10 variants in different copies of the gene: c.766C>T, producing p.Arg256*, and c.539G>A, producing p.Gly180Glu. Sanger sequencing confirmed that one came from each parent. The authors classified the first as pathogenic and the second as likely pathogenic, then combined those findings with the multisystem clinical presentation to diagnose Bardet-Biedl syndrome^[2]. Genetic confirmation is a separate finding from the later treatment observation. It does not turn the metabolic follow-up into a controlled experiment.

What changed during follow-up

The paper reports a semaglutide schedule that increased over the first nine weeks and continued for six months. That schedule describes this patient's care and is not guidance for readers. No other antihyperglycemic agent was coadministered during the reported treatment period. HbA1c fell from 8.5% at baseline to 7.2% at three months and 6.1% at six months. Fasting plasma glucose fell from 13.75 to 8.43 and then 6.99 mmol/l^[2].

Other recorded measures moved in the same direction. Body weight fell from 80 to 75 and then 71 kg, while body mass index fell from 31.6 to 29.6 and then 28 kg/m2. Fasting insulin declined from 25.34 to 12.88 micro-units/ml, and the reported HOMA-IR estimate declined from 15.5 to 4. The authors reported no adverse events during six months^[2]. One person's absence of a reported adverse event provides little evidence about safety. Broader safety information belongs in the semaglutide safety overview.

Kidney measurements changed markedly. Estimated glomerular filtration rate rose from 48.1 to 119 ml/min/1.73 m2 at three months and was 107 at six months; serum creatinine fell from 127.8 to 52.2 and then 56.3 micromol/l^[2]. The authors proposed contributions from improved glycemic control, resolution of acute physiological stress and a direct drug effect. The design cannot separate those explanations. A changing creatinine value in one clinically complex patient does not demonstrate kidney protection.

Why the mechanism remains hypothetical

Bardet-Biedl syndrome is a ciliopathy. The BBSome helps traffic signaling molecules to and from the primary cilium, and BBS10 contributes to assembly of that protein complex. The authors propose that semaglutide might still engage residual cilia-dependent or other GLP-1 receptor signaling despite disrupted ciliary trafficking^[2]. They did not measure receptor localization, cyclic AMP signaling or genotype-specific drug response in this patient. The proposed pathway is biologically framed speculation, not a mechanism demonstrated by the case.

The paper calls for work in patient-derived cells or animal models to test the signaling hypothesis. Human evidence would also need more than selected case reports. A cohort with defined entry criteria and consistent follow-up could describe outcomes across people with BBS. A controlled design would be needed to estimate how much change is attributable to treatment rather than concurrent care, natural variation or regression toward usual values. Our semaglutide research summary covers evidence from larger study designs.

What we do not yet know

The report cannot estimate efficacy, comparative effectiveness or adverse-event rates in Bardet-Biedl syndrome. Follow-up lasted only from April to October 2025. The patient had several metabolic and renal abnormalities, and the clinical setting allowed many factors to change together. At admission, the report recorded protein and white blood cells in urine as well as a history of inconsistent metformin use. Later measurements could therefore reflect changes in acute illness, adherence, diet or other clinical care alongside semaglutide. There was no untreated comparison, no repeated pretreatment baseline, no masking and no protocol designed to isolate semaglutide's contribution. Publication of a notable response also creates selection risk because ordinary or unfavorable courses may be less likely to appear as case reports.

The authors obtained ethics approval and written consent, declared no competing interests and disclosed grant support from a regional research center^[2]. Those disclosures help readers assess the report, but they do not overcome the design limits. The sound conclusion is narrow: several metabolic measurements improved over six months in one genetically characterized patient. Whether semaglutide has a reproducible benefit specific to BBS10-related disease remains unanswered.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.